Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

ASTRA COUNTING ON LONG-TERM INDICATION FOR PRILOSEC HELP PAY OFF $820 MIL. BUY-IN TO ASTRA MERCK; JOINT VENTURE SALES ARE $860 MIL THROUGH NINE MONTHS

  • News

Executive Summary

Astra is looking to a long-term indication for Prilosec to help pay off its $820 mil. investment in Astra Merck, Inc.

You may also be interested in...



AstraZeneca Tonocard discontinuation

AstraZeneca will discontinue Tonocard (tocainide) in U.S. Dec. 31. Approved in 1984 to treat severe irregular heartbeat, company says newer products now dominate market. Tonocard was one of original Astra Merck collaborations (1"The Pink Sheet" Nov. 7, 1994, p. 9). Merck currently manufacturers the drug for AstraZeneca. Worldwide sales in 2002 were approximately $1.2 mil., the bulk of which were in the U.S, AstraZeneca says...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS025247

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By